Latest News
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
18 September 2026 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) confirmed on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has maintained its negative opinion o...
Abbott declares 411th consecutive quarterly dividend
18 September 2026 - Global healthcare company Abbott (NYSE:ABT) announced on Thursday that its board of directors has declared a quarterly dividend of USD0.63 per share of common stock.This marks the 411th consecutive quarterly dividend to be paid by...
Kemp Proteins partners with NeuImmune to advance precision protein production
18 September 2026 - Kemp Proteins LLC, a contract research and manufacturing organisation, announced on Thursday that it is expanding its cell line development and recombinant protein production capabilities through a strategic partnership with biote...
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
18 September 2026 - Otsuka ICU Medical LLC, a manufacturer of IV solutions for healthcare providers, announced on Thursday that it is issuing a voluntary recall for one lot of 0.9% SODIUM CHLORIDE Injection, USP, 100mL single pack to the user level d...
Genentech's Lunsumio regimen improves progression-free survival in Phase III follicular lymphoma study
17 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Thursday that its Phase III CELESTIMO study of Lunsumio (mosunetuzumab-axgb) plus lenalidomide met its primary endpoint in re...